Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL
Critère d'inclusion
- Burkitt lymphoma